Comparison of the efficacy of cilofungin, fluconazole and amphotericin B in the treatment of systemic Candida albicans infection in the neutropenic mouse.
The relative efficacies of cilofungin, amphotericin B and fluconazole were compared in the treatment of systemic Candida albicans infection in neutropenic mice. Thirty-one day survival rates were lowest for cilofungin (14.6%), intermediate for amphotericin B (37.6%) and highest for fluconazole (50.5%). Residual tissue infection in surviving animals was observed with all agents, but was heaviest with fluconazole, especially in the kidneys.
Bannatyne
R M
RM
Dept. of Microbiology, St. Micheal's Hospital, Toronto, Canada.
Cheng
P C
PC
Fong
I W
IW
D000666:Amphotericin B / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000935:Antifungal Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D015169:Colony Count, Microbial; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D054714:Echinocandins; D005260:Female; D015725:Fluconazole / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D016469:Fungemia / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D007668:Kidney / Q000382:microbiology; D008099:Liver / Q000382:microbiology; D008168:Lung / Q000382:microbiology; D051379:Mice; D009503:Neutropenia / Q000150:complications; D010455:Peptides / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D010456:Peptides, Cyclic; D013154:Spleen / Q000382:microbiology; D015996:Survival Rate
D000935:Antifungal Agents; D054714:Echinocandins; D010455:Peptides; D010456:Peptides, Cyclic; D000666:Amphotericin B; D015725:Fluconazole; C042101:cilofungin